- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03964142
Exercise-based Cardiac Rehabilitation for the Prevention of Breast Cancer Chemotherapy-induced Cardiotoxicity (ONCORE)
Randomized Controlled Trial on Comprehensive Exercise-based Cardiac Rehabilitation Programs for the Prevention of Anthracyclines and/or Anti-HER2 Antibodies-induced Cardiotoxicity in Breast Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Cardiovascular toxicity caused by chemotherapy is the leading cause of death in patients who survive cancer. Physical exercise during chemotherapy has shown to improve quality of life and decrease the risk of death. The objective of this project is to determine whether an intervention through a comprehensive cardiac rehabilitation program including supervised physical exercise is able to prevent anthracyclines and / or anti-HER-2 antibodies-induced cardiotoxicity in women with breast cancer.
For this purpose, the investigators intend to conduct a randomized controlled study including female patients managed under the same cardiotoxicity prevention protocol (clinical, laboratory and echocardiographic follow-up assessment). Patients will be randomized to a non-pharmacological intervention (participation in a multidisciplinary cardiac rehabilitation program with supervised exercise training) or control (conventional management and physical activity recommendation)*.
The investigators hypothesize that a cardiac rehabilitation program may limit chemotherapy-induced cardiotoxicity in women with breast cancer, improve cardiac remodeling assessed by echocardiography and enhance their global cardiovascular risk profile to a greater extent, compared to control group.
* OF NOTE: Due to the COVID-19 pandemics, several modifications to the original protocol were introduced for safety reasons or motivated by the health situation, namely:
- Intervention: Change from centre-based to telematic supervised exercise training sessions provided within the cardiac rehabilitation program (intervention group)
- Secondary outcome 4: Change in functional capacity assessed by conventional ergometry or cardiopulmonary exercise test OR the 6-minute walking test (metabolic equivalents: METs or peak oxygen consumption: VO2)
- Recruiting centres: One centre (Hospital Universitari Vall d'Hebron) withdrew from the study due to the impossibility of assuming its execution.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
A Coruña
-
Santiago de Compostela, A Coruña, Spain, 15706
- Hospital Clinico Universitario de Santiago
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- First diagnosis of breast cancer at early stages (I, II, III)
- Treatment with anthracyclines and / or anti-HER-2 antibodies (trastuzumab and / or pertuzumab)
- Possibility of completing a cardiac rehabilitation program (centre-based or telematic) and programmed visits.
- Providing written informed consent.
Exclusion Criteria:
- Patients with previous history of heart disease or heart failure.
- Left ventricular dysfunction (left ventricular ejection fraction <53%) at baseline.
- Metastatic disease.
- Patients carrying an implantable cardioverter defibrillator.
- Patients with physical or mental limitation to carry out an exercise program.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cardiac Rehabilitation
Patients enrolled in the integrated exercise-based cardiac rehabilitation program (centre-based or telematic)
|
Integrated cardiac rehabilitation program that includes supervised exercise training*. * Due to the COVID-19 pandemic, supervised physical exercise training had to be conducted telematically (through live guided training sessions conducted online, with the same design, frequency, and dosage of exercise). |
No Intervention: Conventional management
Patients with conventional management and physical activity recommendation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in left ventricular systolic function quantified by left ventricular ejection fraction and global longitudinal strain by transthoracic echocardiography
Time Frame: Baseline to every 3 months through study completion, at the end of the study at an average of 18 months, and every year after study completion up to a maximum of 5 years
|
Fall of 10 absolute percentage points of left ventricular ejection fraction with final value below 53% or global longitudinal strain fall >15% with respect to baseline
|
Baseline to every 3 months through study completion, at the end of the study at an average of 18 months, and every year after study completion up to a maximum of 5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in health-related quality of life assessed by the Functional Assessment of Cancer Therapy - Breast plus Arm Morbidity (FACT-B+4) questionnaire
Time Frame: Baseline and at the end of the study at an average of 18 months
|
Score achieved in the Functional Assessment of Cancer Therapy - Breast plus Arm Morbidity (FACT-B+4) questionnaire, a specific validated scale to assess quality of life of women with breast cancer.
It comprises 27 items within 5 areas of assessment: physical well-being (7 items), social and family environment (7 items), emotional well-being (7 items), functional well-being (6 items) and worries related to the diagnosis and treatment of the disease (9 items).
Each item is scored by means of a Likert scale from 0 to 5, with higher scores representing better results.
The total score is obtained by adding the scores for each item, and ranges from a minimum of 0 (worst posible result) to a maximum of 146 (best possible result).
|
Baseline and at the end of the study at an average of 18 months
|
Change in tolerance to chemotherapy: number of participants with significant cardiovascular and non-cardiovascular adverse effects throughout the study
Time Frame: Every 3 months during study completion and at the end of the study at an average of 18 months
|
Significant cardiovascular and non-cardiovascular adverse effects during treatment, threatening life, requiring admission, prolonging hospitalization, being clinically relevant or causing chemotherapy interruptions
|
Every 3 months during study completion and at the end of the study at an average of 18 months
|
Change in global functional capacity assessed by conventional ergometry, cardiopulmonary exercise testing (CPET) or the 6-minute walking test (6MWT).
Time Frame: Baseline and at the end of the study at an average of 18 months
|
Change in functional capacity assessed by conventional ergometry, cardiopulmonary exercise test or the 6-minute walking test (6MWT) (metabolic equivalents: METs or peak oxygen consumption: VO2) * . *Due to COVID-19 pandemic, participants' assessment with CPET had to be stopped for safety concerns. In such cases, functional capacity was estimated from the maximum work rate in the 6-minute walking test (6MWT). This test measures the distance that a patient can quickly walk on a flat, hard surface in a period of 6 minutes, which is well correlated with VO2. The 6MWT has been proved to be valid and reliable for functional capacity assessment in the study population. |
Baseline and at the end of the study at an average of 18 months
|
Change in localized lower limb functional capacity assessed by number of repetitions performed within 30 seconds in the sit-to-stand test
Time Frame: Baseline and at the end of the study at an average of 18 months
|
Number of repetitions in the sit-to-stand test within 30 seconds
|
Baseline and at the end of the study at an average of 18 months
|
Change in shoulder functional capacity assessed by range of degrees in shoulder movement by goniometry
Time Frame: Baseline and at the end of the study at an average of 18 months
|
Range of degrees in shoulder movement measured by goniometry
|
Baseline and at the end of the study at an average of 18 months
|
Change in upper limb strength measured by dynamometry (kg)
Time Frame: Baseline and at the end of the study at an average of 18 months
|
Kilograms by dynamometry of right and left upper limbs
|
Baseline and at the end of the study at an average of 18 months
|
Change in shoulder pain and disability assessed by the SPADI (shoulder pain and disability index (SPADI) questionnaire
Time Frame: Baseline and at the end of the study at an average of 18 months
|
Score achieved in the SPADI (shoulder pain and disability index) questionnaire.
The pain dimension consists of five questions regarding the severity of an individual's pain, functional activities are assessed with eight questions.
Each question may be scored from 0 to 10. Verbal anchors for the pain dimension are 'no pain at all' (0) and 'worst pain imaginable' (10) ,and those for the functional activities are 'no difficulty' (0) and 'so difficult it required help' (10).
The scores from both dimensions are averaged to produce a total score ranging from 0 (best) to 100 (worst).
|
Baseline and at the end of the study at an average of 18 months
|
Change in cardiovascular risk profile as assessed by the presence or absence of classic cardiovascular risk factors
Time Frame: Baseline and at the end of the study at an average of 18 months
|
Dyslipidemia, Diabetes mellitus, Arterial Hypertension, Smoking status
|
Baseline and at the end of the study at an average of 18 months
|
Change in anthropometric parameters: height in cm
Time Frame: Baseline and at the end of the study at an average of 18 months
|
Height measured in cm
|
Baseline and at the end of the study at an average of 18 months
|
Change in anthropometric parameters: weight in kg
Time Frame: Baseline and at the end of the study at an average of 18 months
|
Weight measured in kg
|
Baseline and at the end of the study at an average of 18 months
|
Change in anthropometric parameters: body mass index (BMI) in kg/m^2
Time Frame: Baseline and at the end of the study at an average of 18 months
|
Weight and height will be combined to report BMI in kg/m^2
|
Baseline and at the end of the study at an average of 18 months
|
Change in anthropometric parameters: abdominal circumference in cm
Time Frame: Baseline and at the end of the study at an average of 18 months
|
Abdominal perimeter measured with a tape measure in cm
|
Baseline and at the end of the study at an average of 18 months
|
Change in resting heart rate measured by pulse oximetry (beats per min)
Time Frame: Baseline and at the end of the study at an average of 18 months
|
Resting heart rate by pulse oximetry (beats per min)
|
Baseline and at the end of the study at an average of 18 months
|
Change in resting blood pressure (mmHg) measured by sphygmomanometer
Time Frame: Baseline and at the end of the study at an average of 18 months
|
Resting blood pressure by sphyngomanometer in mmHg
|
Baseline and at the end of the study at an average of 18 months
|
Change in biomarkers NT-ProBNP
Time Frame: Baseline and at the end of the study at an average of 18 months
|
Value of NT-ProBNP(pg/mL) in blood tests
|
Baseline and at the end of the study at an average of 18 months
|
Change in biomarkers: troponin
Time Frame: Baseline and at the end of the study at an average of 18 months
|
Value of troponin I (ng/mL) in blood tests
|
Baseline and at the end of the study at an average of 18 months
|
Change in biomarkers: haemoglobin
Time Frame: Baseline and at the end of the study at an average of 18 months
|
Value of haemoglobin (g/dL) in blood tests
|
Baseline and at the end of the study at an average of 18 months
|
Change in dietary pattern as assessed by the PREDIMED (PREvención con DIeta MEDiterránea) questionnaire
Time Frame: Baseline and at the end of the study at an average of 18 months
|
Validated questionnaire to assess adherence to Mediterranean diet, including 14 questions regarding dietary habits, rated with 0 or +1 points.
Global score is calculated by summing points and ranges from 0 to 14, with higher score representing higher adherence.
|
Baseline and at the end of the study at an average of 18 months
|
Change in the score for depression assessed by Zigmond and Snaith questionnaire to rate anxiety and depression
Time Frame: Baseline and at study completion at an average of 18 months, plus at the end of training (at an average of 12 to 15 months) in the intervention group
|
Score achieved in the depression subscale of the Zigmond and Snaith test for anxiety or depression, a self-applied questionnaire.
Depression scale includes 7 items each, scored on Likert scale from 0 to 3. Global score ranges from 0 to 21, with higher scores representing greater depression.
The authors suggest that scores higher than eleven would indicate "case" and more than eight would be considered "probable case" (Zigmond and Snaith, 1983).
|
Baseline and at study completion at an average of 18 months, plus at the end of training (at an average of 12 to 15 months) in the intervention group
|
Change in the score for anxiety assessed by the Zigmond and Snaith questionnaire to rate depression and anxiety
Time Frame: Baseline and at study completion, plus at the end of training (at an average of 12 to 15 months) in the intervention group
|
Score achieved in the anxiety subscale of the Zigmond and Snaith test for anxiety or depression, a self-applied questionnaire.
Anxiety scale includes 7 items each, scored on Likert scale from 0 to 3. Global score ranges from 0 to 21, with higher scores representing greater anxiety.
The authors suggest that scores higher than eleven would indicate "case" and more than eight would be considered "probable case" (Zigmond and Snaith, 1983).
|
Baseline and at study completion, plus at the end of training (at an average of 12 to 15 months) in the intervention group
|
Change in physical activity (minutes of dedicated physical activity)
Time Frame: Baseline and at study completion at an average of 18 months
|
Minutes of In- and out-of-hospital dedicated physical activity
|
Baseline and at study completion at an average of 18 months
|
Change in physical activity assessed by the score in the Godin Leisure Test Exercise Questionnaire (GLTEQ)
Time Frame: Baseline and at study completion at an average of 18 months
|
Score achieved in the Godin Leisure Test Exercise Questionnaire (GLTEQ) for quantification of physical activity.
Activities are classified into three subgroups: "strenuous," "moderate," and "light."
The scores corresponding to the energy expenditure (metabolic equivalent (MET)) are obtained by multiplying activities performed for more than 15 min in a week with their coefficients.
The numbers represent the MET intensity values (strenuous/ exhausting exercises: 9 METs, moderate exercises: 5 METs, and light exercises: 3 METs).The increasing scores are associated with the increasing number of exercise behaviors, providing references about the contribution of physical activity to health: the activity score of 24 units and more as active (substantial benefits); the activity score of 14-23 units as moderately active (some benefits); and the activity score of 13 units and less as inactive (less substantial or low benefits).
|
Baseline and at study completion at an average of 18 months
|
Change in lymphedema assessed by perimeter of the upper limb by cirtometry (cm), stage and grade
Time Frame: Baseline after surgery and 2-4 weeks after the end of chemotherapy (at an average of 12 to 15 months)
|
Perimeter of the upper limb by cirtometry (cm), stage and grade as defined by the Spanish Society of Rehabilitation and Physical Medicine
|
Baseline after surgery and 2-4 weeks after the end of chemotherapy (at an average of 12 to 15 months)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adherence and compliance to cardiac rehabilitation program (intervention group) assessed by number of training sessions attended/ number of sessions planned
Time Frame: At the end of the cardiac rehabilitation program at an average of 12 to 15 months
|
Number of training sessions attended / number of sessions planned
|
At the end of the cardiac rehabilitation program at an average of 12 to 15 months
|
Security of the cardiac rehabilitation program assessed by number of adverse events during training (intervention group)
Time Frame: At the end of the cardiac rehabilitation program at an average of 12 to 15 months
|
Adverse events during training
|
At the end of the cardiac rehabilitation program at an average of 12 to 15 months
|
Changes in expectations regarding the cardiac rehabilitation program assessed by a questionnaire (intervention group)
Time Frame: Baseline and at the end of the cardiac rehabilitation program at an average of 12 to 15 months
|
Program-related expectations at baseline and at the end of the program' are collected through an open question "What do you expect to achieve by participating in the program?"
Responses regarding expectations will be categorized by the evaluator within the following areas: psychological sphere and/or social sphere and/or physical sphere.
Global expectations of benefit are scored from 0 (no benefit) to 10 (highest benefit).
|
Baseline and at the end of the cardiac rehabilitation program at an average of 12 to 15 months
|
Satisfaction with the cardiac rehabilitation program assessed by a questionnaire (intervention group)
Time Frame: At the end of the cardiac rehabilitation program at an average of 12 to 15 months
|
Satisfaction at the end of the program is assessed by a questionnaire including 9 questions concerning comfort with training sessions, training spaces and development of the program, which are scored from 0 (worse posible result) to 10 (best posible result). Total score is calculated by adding for each question, and ranges from 0 to 90. * Due to the introduction of telematic exercise training during COVID-19 pandemic, questions were slightly modified to include assessment of satisfaction with this training modality. |
At the end of the cardiac rehabilitation program at an average of 12 to 15 months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Amparo Martínez Monzonís, MD, PhD, Cardiology Department, Hospital Clínico Universitario de Santiago, CIBER-CV
- Principal Investigator: Carlos Peña Gil, MD, PhD, Cardiology Department, Hospital Clínico Universitario de Santiago, CIBER-CV
- Study Director: José Ramón González Juanatey, MD, PhD, Cardiology Department, Hospital Clínico Universitario de Santiago, CIBER-CV
Publications and helpful links
General Publications
- Diaz-Balboa E, Gonzalez-Salvado V, Rodriguez-Romero B, Martinez-Monzonis A, Pedreira-Perez M, Cuesta-Vargas AI, Lopez-Lopez R, Gonzalez-Juanatey JR, Pena-Gil C. Thirty-second sit-to-stand test as an alternative for estimating peak oxygen uptake and 6-min walking distance in women with breast cancer: a cross-sectional study. Support Care Cancer. 2022 Oct;30(10):8251-8260. doi: 10.1007/s00520-022-07268-z. Epub 2022 Jul 11.
- Diaz-Balboa E, Gonzalez-Salvado V, Rodriguez-Romero B, Martinez-Monzonis A, Pedreira-Perez M, Palacios-Ozores P, Lopez-Lopez R, Pena-Gil C, Gonzalez-Juanatey JR. A randomized trial to evaluate the impact of exercise-based cardiac rehabilitation for the prevention of chemotherapy-induced cardiotoxicity in patients with breast cancer: ONCORE study protocol. BMC Cardiovasc Disord. 2021 Apr 7;21(1):165. doi: 10.1186/s12872-021-01970-2.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PI17/01687
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiotoxicity
-
The Hospital for Sick ChildrenCanadian Institutes of Health Research (CIHR); London Health Sciences Centre; Children's Hospital of Eastern Ontario and other collaboratorsCompletedAnthracycline-induced CardiotoxicityUnited States, Canada
-
West China Second University HospitalRecruitingImmune Checkpoint Inhibitors, CardiotoxicityChina
-
McGill University Health Centre/Research Institute...UnknownChemotherapy, Cancer, Cardiotoxicity, PhysioflowCanada
-
Queen's University, BelfastActive, not recruitingAnthracycline Induced CardiotoxicityUnited Kingdom
-
TC Erciyes UniversityCompletedAnthracycline Induced CardiotoxicityTurkey
-
Yonsei UniversityRecruitingChemotherapy Induced CardiotoxicityKorea, Republic of
-
Texas Tech University Health Sciences CenterRecruitingAnthracycline Related Cardiotoxicity in Breast CancerUnited States
-
Memorial Sloan Kettering Cancer CenterCompletedChemotherapy Induced Cardiotoxicity in Breast Cancer PatientsUnited States
-
Zhejiang Cancer HospitalRecruitingCardiotoxicity Induced by Drug Therapy for Breast CancerChina
-
Rambam Health Care CampusUnknownMetastatic Breast Cancer | Cardiotoxicity. | Anti Her2 Therapy.Israel
Clinical Trials on Cardiac rehabilitation
-
Wake Forest University Health SciencesRecruitingCardiac AmyloidosisUnited States
-
Lawson Health Research InstituteHeart and Stroke Foundation of OntarioCompleted
-
Duke UniversityNational Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Heart DiseaseUnited States
-
Lawson Health Research InstituteCanadian Institutes of Health Research (CIHR); AstraZenecaCompletedMyocardial Infarction | Coronary Disease | Unstable AnginaCanada
-
Cairo UniversityNational Heart Institute, EgyptCompletedChronic Heart FailureEgypt
-
University of California, San FranciscoPatient-Centered Outcomes Research Institute; Johns Hopkins University; Mayo... and other collaboratorsRecruitingMyocardial Infarction | Coronary Artery Disease | Heart Valve Diseases | Angina, Stable | Heart Failure, Systolic | Heart TransplantUnited States
-
Federico II UniversityCompletedAcute Myocardial InfarctionItaly
-
Women's College HospitalRecruiting
-
Fundación Pública Andaluza para la Investigación...UnknownHomebased Cardiac Rehabilitation Program After Ischemic Heart DiseaseSpain
-
Universidade do PortoCentro Hospitalar de Vila Nova de Gaia/Espinho; Research Center in Physical...CompletedCoronary Artery DiseasePortugal